Naloxegol

• UNSPSC Description:

  Naloxegol (NKTR-118; AZ-13337019) is a μ-opioid-receptor antagonist. Naloxegol inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation[1][2].

• Target Antigen:

  Opioid Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein;Neuronal Signaling

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Naloxegol.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O[C@@]1(CC[C@H](OCCOCCOCCOCCOCCOCCOCCOC)[C@]2([H])OC3=C4O)[C@]52C3=C(C=C4)C[C@@]1([H])N(CC=C)CC5

• Molecular Weight:

  651.78

• References & Citations:

  [1]Yoon SC, et al. Naloxegol in opioid-induced constipation: a new paradigm in the treatment of a common problem. Patient Prefer Adherence. 2017 Jul 24;11:1265-1271.|[2]Garnock-Jones KP, et al. Naloxegol: a review of its use in patients with opioid-induced constipation. Drugs. 2015 Mar;75(4):419-25.Front Immunol. 2021 Jul 7;12:692286.|Eur J Pharmacol. 2021 Apr 29;174132.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Launched

• CAS Number:

  854601-70-0